BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. Infect Drug Resist 2018;11:2117-27. [PMID: 30464554 DOI: 10.2147/IDR.S179158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Morsica G, Vercesi R, Hasson H, Messina E, Uberti-Foppa C, Bagaglio S. Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype. Viruses 2021;13:1486. [PMID: 34452351 DOI: 10.3390/v13081486] [Reference Citation Analysis]
2 Amer F, Yousif MM, Hammad NM, Garcia-Cehic D, Gregori J, Rando-Segura A, Nieto-Aponte L, Esteban JI, Rodriguez-Frias F, Quer J. Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment. Infect Drug Resist 2019;12:2799-807. [PMID: 31571936 DOI: 10.2147/IDR.S214735] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Marascio N, Mazzitelli M, Pavia G, Giancotti A, Barreca GS, Costa C, Pisani V, Greco G, Serapide F, Trecarichi EM, Casalinuovo F, Liberto MC, Matera G, Torti C. Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. Cells. 2019;8. [PMID: 31060315 DOI: 10.3390/cells8050416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]